{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:41:34Z","timestamp":1793695294769,"version":"4.5.1"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2020,12,8]]},"DOI":"10.1001\/jama.2020.22960","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T22:49:15Z","timestamp":1607554155000},"page":"2282","source":"Crossref","is-referenced-by-count":69,"title":["Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis"],"prefix":"10.1001","volume":"324","author":[{"given":"Andrew M.","family":"Wilson","sequence":"first","affiliation":[{"name":"Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, Norfolk, United Kingdom"},{"name":"Department of Respiratory Medicine, Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, Norfolk, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan B.","family":"Clark","sequence":"additional","affiliation":[{"name":"Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, Norfolk, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Cahn","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Bedford Hospitals NHS Trust, South Wing, Bedford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin R.","family":"Chilvers","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Fraser","sequence":"additional","affiliation":[{"name":"Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, Norfolk, United Kingdom"},{"name":"Department of Endocrinology and Clinical Biochemistry, Norfolk and Norwich University Hospital NHS Foundation Trust, Colney Lane, Norwich, Norfolk, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hammond","sequence":"additional","affiliation":[{"name":"Norwich Clinical Trials Unit, University of East Anglia, Norwich Research Park, Norwich, Norfolk, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Livermore","sequence":"additional","affiliation":[{"name":"Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, Norfolk, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby M.","family":"Maher","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Clinical Biochemistry, Norfolk and Norwich University Hospital NHS Foundation Trust, Colney Lane, Norwich, Norfolk, United Kingdom"},{"name":"Hastings Centre for Pulmonary Research and Division of Pulmonary, Critical Care and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles"},{"name":"NIHR Respiratory Clinical Research Facility, Royal Brompton Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Parfrey","sequence":"additional","affiliation":[{"name":"Royal Papworth Hospital NHS Foundation Trust, Papworth Road, Cambridge Biomedical Campus, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Marie","family":"Swart","sequence":"additional","affiliation":[{"name":"Norwich Clinical Trials Unit, University of East Anglia, Norwich Research Park, Norwich, Norfolk, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Stirling","sequence":"additional","affiliation":[{"name":"Norwich Clinical Trials Unit, University of East Anglia, Norwich Research Park, Norwich, Norfolk, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Thickett","sequence":"additional","affiliation":[{"name":"Institute of Inflammation and Aging, University of Birmingham, Edgbaston, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moira","family":"Whyte","sequence":"additional","affiliation":[{"name":"MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the EME-TIPAC team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"joi200122r1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12931-018-0845-5","article-title":"The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis.","volume":"19","author":"Guenther","year":"2018","journal-title":"Respir Res"},{"issue":"6","key":"joi200122r2","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/thx.2010.148031","article-title":"The rising incidence of idiopathic pulmonary fibrosis in the UK.","volume":"66","author":"Navaratnam","year":"2011","journal-title":"Thorax"},{"issue":"2","key":"joi200122r3","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.rmed.2013.11.007","article-title":"Outcomes in idiopathic pulmonary fibrosis: a meta-analysis from placebo controlled trials.","volume":"108","author":"Atkins","year":"2014","journal-title":"Respir Med"},{"issue":"8","key":"joi200122r4","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1136\/thx.2008.110445","article-title":"Pulmonary infection in Wegener granulomatosis and idiopathic pulmonary fibrosis.","volume":"64","author":"Richter","year":"2009","journal-title":"Thorax"},{"issue":"3","key":"joi200122r5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1469-0691.2005.01337.x","article-title":"Pneumocystis jirovecii colonisation in patients with interstitial lung disease.","volume":"12","author":"Vidal","year":"2006","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"joi200122r6","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/thoraxjnl-2012-202917","article-title":"Microbial communities in the respiratory tract of patients with interstitial lung disease.","volume":"68","author":"Garzoni","year":"2013","journal-title":"Thorax"},{"issue":"8","key":"joi200122r7","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1164\/rccm.201403-0541OC","article-title":"The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis.","volume":"190","author":"Molyneaux","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"joi200122r8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008578","article-title":"Disordered microbial communities in asthmatic airways.","volume":"5","author":"Hilty","year":"2010","journal-title":"PLoS One"},{"issue":"7","key":"joi200122r9","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S2213-2600(14)70069-4","article-title":"Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study.","volume":"2","author":"Han","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"1","key":"joi200122r10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1164\/ajrccm\/139.1.22","article-title":"Bronchoalveolar macrophages from patients with idiopathic pulmonary fibrosis are unable to kill facultative intracellular bacteria.","volume":"139","author":"Savici","year":"1989","journal-title":"Am Rev Respir Dis"},{"issue":"5","key":"joi200122r11","first-page":"1397","article-title":"Expression profiles of Toll-like receptors in non-small cell lung cancer and idiopathic pulmonary fibrosis.","volume":"40","author":"Samara","year":"2012","journal-title":"Int J Oncol"},{"issue":"1","key":"joi200122r12","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.pupt.2007.02.001","article-title":"A double blind randomised placebo controlled pilot study of oral co-trimoxazole in advanced fibrotic lung disease.","volume":"21","author":"Varney","year":"2008","journal-title":"Pulm Pharmacol Ther"},{"issue":"2","key":"joi200122r13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1136\/thoraxjnl-2012-202403","article-title":"Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial.","volume":"68","author":"Shulgina","year":"2013","journal-title":"Thorax"},{"issue":"1","key":"joi200122r14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40273-013-0112-z","article-title":"Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: an economic evaluation alongside a randomised controlled trial.","volume":"32","author":"Wilson","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"joi200122r15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13063-018-2453-6","article-title":"The efficacy and mechanism evaluation of treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial.","volume":"19","author":"Hammond","year":"2018","journal-title":"Trials"},{"issue":"6","key":"joi200122r16","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"joi200122r17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry.","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"issue":"4","key":"joi200122r18","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1183\/09031936.05.00034905","article-title":"Standardisation of the single-breath determination of carbon monoxide uptake in the lung.","volume":"26","author":"Macintyre","year":"2005","journal-title":"Eur Respir J"},{"key":"joi200122r19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2466-10-32","article-title":"MRC chronic Dyspnea Scale: relationships with cardiopulmonary exercise testing and 6-minute walk test in idiopathic pulmonary fibrosis patients: a prospective study.","volume":"10","author":"Manali","year":"2010","journal-title":"BMC Pulm Med"},{"issue":"10","key":"joi200122r20","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"4","key":"joi200122r21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/thorax.58.4.339","article-title":"Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ).","volume":"58","author":"Birring","year":"2003","journal-title":"Thorax"},{"issue":"9","key":"joi200122r22","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/thoraxjnl-2012-201581","article-title":"The development and validation of the King\u2019s Brief Interstitial Lung Disease (K-BILD) health status questionnaire.","volume":"67","author":"Patel","year":"2012","journal-title":"Thorax"},{"issue":"5","key":"joi200122r23","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets.","volume":"15","author":"van Hout","year":"2012","journal-title":"Value Health"},{"issue":"1","key":"joi200122r24","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2018-000363","article-title":"The King\u2019s Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference.","volume":"6","author":"Sinha","year":"2019","journal-title":"BMJ Open Respir Res"},{"issue":"4","key":"joi200122r25","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice.","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"issue":"21","key":"joi200122r26","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.","volume":"366","author":"Raghu","year":"2012","journal-title":"N Engl J Med"},{"issue":"3-b Suppl","key":"joi200122r27","first-page":"S17","article-title":"Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis.","volume":"23","author":"Fisher","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"joi200122r28","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01519-2019","article-title":"Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent.","volume":"55","author":"Invernizzi","year":"2020","journal-title":"Eur Respir J"},{"key":"joi200122r29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.rmed.2019.04.016","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.","volume":"153","author":"Nathan","year":"2019","journal-title":"Respir Med"},{"issue":"9779","key":"joi200122r30","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"joi200122r31","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1164\/ajrccm\/145.6.1321","article-title":"A self-complete measure of health status for chronic airflow limitation: the St. George\u2019s Respiratory Questionnaire.","volume":"145","author":"Jones","year":"1992","journal-title":"Am Rev Respir Dis"},{"issue":"8181","key":"joi200122r32","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/S0140-6736(80)91732-8","article-title":"Comparison of trimethoprim alone with trimethoprim sulphamethoxazole in the treatment of respiratory and urinary infections with particular reference to selection of trimethoprim resistance.","volume":"1","author":"Lacey","year":"1980","journal-title":"Lancet"},{"issue":"1","key":"joi200122r33","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12931-020-1326-1","article-title":"Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy: the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in idiopathic pulmonary fibrosis (CleanUP-IPF) clinical trial.","volume":"21","author":"Anstrom","year":"2020","journal-title":"Respir Res"},{"issue":"5","key":"joi200122r34","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/thoraxjnl-2017-211220","article-title":"A big beautiful wall against infection.","volume":"73","author":"Jenkins","year":"2018","journal-title":"Thorax"},{"issue":"11","key":"joi200122r35","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1136\/thoraxjnl-2012-202580","article-title":"Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good.","volume":"67","author":"Wells","year":"2012","journal-title":"Thorax"},{"issue":"3","key":"joi200122r36","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: an international working group report.","volume":"194","author":"Collard","year":"2016","journal-title":"Am J Respir Crit Care Med"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2773680\/jama_wilson_2020_oi_200122_1607119465.0611.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T22:49:31Z","timestamp":1607554171000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2773680"}},"subtitle":["The EME-TIPAC Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,12,8]]},"references-count":36,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2020,12,8]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2020.22960","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,8]]}}}